Junjian Liu

Junjian Liu

Company: Innovent Biologics

Job title: Vice President, Head of Drug Discovery & Preclinical Development


Dr. Junjian Liu is Vice President, Head of Drug Discovery & Preclinical Development at Innovent Biologics, responsible for identifying novel antibody therapeutics and developing early R&D pipeline. Prior to Innovent, he had held various research and managerial positions at WuXi AppTec, AbbVie, Abbott Laboratories, etc. Dr. Liu had built several multi-functional discovery teams covering from early research to preclinical development. He had advanced more than 30 biotherapeutic pipeline projects, and developed several novel antibody format platforms including bispecific antibodies. Several of the molecules he discovered have reached various clinical development stages.

Dr. Liu earned his PhD degree from Peking University, followed by 4 years of postdoctoral training at Northwestern University in Chicago. His academic research was focused on molecular mechanism of carcinogenesis.


Safety, Tolerability & Efficacy of CD47 Monoclonal Antibodies in Advanced Malignancies 9:30 am

• Discovery of IBI188, a fully human anti-CD47 therapeutic antibody • Outline preliminary Phase 1 clinical trial results which explore recommended doses for IBI188 in combination • Discuss future direction in CD47 blockadeRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.